

4. Bui HT, Kiroff G, Foy S. Massive pericardial effusion following a laparoscopic adjustable gastric banding. *Obes Surg* 2003; 13: 944–947.
5. Rubenstein RB. Laparoscopic adjustable gastric banding at a US center with up to 3-year follow-up. *Obes Surg* 2002; 12: 380–384.
6. Niville E, Dams A, Vlasselaers J. Lap-Band erosion: incidence and treatment. *Obes Surg* 2001; 11: 744–747.
7. Suter M, Calmes JM, Paroz A, Giusti V. A 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates. *Obes Surg* 2006; 16: 829–835.
8. Suter M, Giusti V, Héraief E, Calmes JM. Band erosion after laparoscopic gastric banding: occurrence and results after conversion to Roux-en-Y gastric bypass. *Obes Surg* 2004; 14: 381–386.
9. Abu-Abeid S, Keidar A, Gavert N, Blanc A, Szold A. The clinical spectrum of band erosion following laparoscopic adjustable silicone gastric banding for morbid obesity. *Surg Endosc* 2003; 17: 861–863.
10. Lewis A, Lasche E, Armstrong A, Dunber F. A clinical study of chronic lung disease due to nonphotochromogenic acid-fast bacilli. *Ann Intern Med* 1960; 53: 273–285.
11. Timpe A, Runyon E. The relationship of atypical acid-fast bacteria to human disease: a preliminary report. *J Lab Clin Med* 1954; 44: 202.
12. Collins C, Grange J, Yates M. Mycobacteria in water. *J Appl Bacteriol* 1984; 57: 193–211.
13. Wolinaky E, Rynearson T. Mycobacteria in soil and their relation to disease associated strains. *Am Rev Respir Dis* 1968; 97: 1032–1037.
14. Rezinokov M, Leggo J, Dawson D. Investigation by seroagglutination of strains of the *Mycobacterium intercellular-M. scarofulacerum* group from house dust to sputum in southeastern Queensland. *Am Rev Respir Dis* 1974; 104: 951–953.
15. Lincoln E, Gilbert A. Disease in children due to mycobacteria other than *Mycobacterium tuberculosis*. *Am Rev Respir Dis* 1972; 105: 683–714.
16. Schaad U, Votteler T, McCracken G. Management of atypical mycobacterial lymphadenitis in childhood: a review based on 380 cases. *J Pediatr* 1979; 95: 356–360.
17. Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. *Clin Infect Dis* 1995; 20: 954–963.
18. Falkinham J. Epidemiology of infection by nontuberculous mycobacteria. *Clin Microbiol Rev* 1996; 9: 177–222.
19. Wolinsky E. State of the art: nontuberculous mycobacteria and associated diseases. *Am Rev Respir Dis* 1979; 119: 107–159.
20. American Thoracic Society. Diagnosis and treatment of diseases caused by nontuberculous mycobacteria. *Am J Resp Crit Care Med* 1997; 156: (suppl) 1–19.
21. Adekambi T, Berger D, Raoult D, Drancourt M. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with description of *Mycobacterium bolletii* sp.nov., *Mycobacterium phocaicum* sp. Nov. and *Mycobacterium aubagnense* sp. Nov. *Int J Syst Evol Microbiol* 2006; 56: 133–143.
22. Adekambi T, Reynaud-Gaubert M, Greub G. Amoebal coculture of *Mycobacterium massiliense* sp. nov. from the sputum of a patient with hemoptoic pneumonia. *J Clin Microbiol* 2004; 42: 5493–5501.
23. Adékambi T, Drancourt M. *Mycobacterium bolletii* respiratory infections. *Emerg Infect Dis* 2009; 15: 302–305.
24. Hanna B, Ebrahimzadeh L, Elliott L, Morgan M, Novak S. Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. *J Clin Microbiol* 1999; 37: 748–752.
25. Rahav G, Pitlik S, Amitai Z, Lavy A, Blech M. An outbreak of *Mycobacterium jacuzzii* infection following insertion of breast implants. *Clin Infect Dis* 2006; 43: 823–830.
26. Primm T, Lucero C, Falkinham J. Health impact of environmental mycobacteria. *Clin Microbiol Rev* 2004; 17: 98–106.
27. Safranek T, Jarvis W, Carson L, Cusick L. *Mycobacterium chelonae* wound infections after plastic surgery employing contaminated gentian violet skin-marking solution. *N Engl J Med* 1987; 317: 197–201.
28. Wallace R, Brown B, Griffith D. Nosocomial outbreak/pseudo-outbreaks caused by nontuberculous mycobacteria. *Ann Rev Microbiol* 1998; 52: 453–490.
29. Meyers H, Brown-Elliott B, Moore D. An outbreak of *Mycobacterium chelonae* infection following liposuction. *Clin Infect Dis* 2002; 34: 1500–1507.
30. Brown-Elliott B, Wallace R. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. *Clin Microbiol Rev* 2002; 15: 716–746.
31. Douglas R, Cook T, Shorr N. Lumps and bumps: late postsurgical inflammatory and infectious lesion. *Plast Reconstr Surg* 2003; 112: 1923–1928.
32. Knackmuhs G, Gerwel M, Patterson G. *Mycobacterium chelonae* infections associated with face lifts – New Jersey, 2002–2003. *MMWR Morb Mortal Wkly Rep* 2004; 53: 192–194.
33. Winthrop K, Abrams M, Yakus M. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. *N Engl J Med* 2002; 346: 1366–1371.
34. Clegg H, Foster M, Snders W, Baine W. Infection due to organisms of the *Mycobacterium fortuitum* complex after augmentation mammoplasty: clinical and epidemiologic features. *J Infect Dis* 1983; 147: 427–433.
35. Clegg H, Bertagnoll P, Hightower A, Baine W. Mammoplasty-associated mycobacterial infection: a survey of plastic surgeons. *Plast Reconstr Surg* 1983; 72: 165–169.
36. Wallace R, Steels L, Labidi A, Silcox A. Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammoplasty despite case clustering in Texas and other southern coastal states. *J Infect Dis* 1989; 160: 281–288.
37. Heistein J, Mangino J, Ruberg R, Bergese J. A prosthetic breast implant infected with *Mycobacterium fortuitum*. *Ann Plast Surg* 2000; 44: 330–333.

Human isolates of *Aeromonas* possess Shiga toxin genes (*stx1* and *stx2*) highly similar to the most virulent gene variants of *Escherichia coli*

A. Alperi and M. J. Figueras

Unitat de Microbiologia, Departament de Ciències Mèdiques Bàsiques, Facultat de Medicina i Ciències de la Salut. IISPV. Universitat Rovira i Virgili, Reus, Spain

Abstract

Strains producing Shiga toxins, encoded by *stx1* and *stx2* genes, can cause diarrhoea, haemorrhagic colitis and haemolytic uremic syndrome. PCR screening of 80 clinical *Aeromonas* strains showed that 19 were *stx1*-positive and only one was positive for both *stx1* and *stx2*. PCR bands were very faint for some strains and negative results were obtained after subculturing. The

obtained sequences of *Aeromonas stx1* and *stx2* genes were highly similar to those of the most virulent *stx* gene variants of Shiga toxin-producing *Escherichia coli*. These results may lead to a better understanding of the potential pathogenicity and virulence mechanisms of *Aeromonas*.

Keywords: *Aeromonas*, diarrhoea, HUS, *stx1*, *stx2*

Original Submission: 14 July 2009; **Revised Submission:** 21

January 2010; **Accepted:** 26 February 2010

Editor: P. Tassios

Article published online: 6 March 2010

Clin Microbiol Infect 2010; **16**: 1563–1567

10.1111/j.1469-0691.2010.03203.x

Corresponding author: M. J. Figueras, Unitat de Microbiologia. Departament de Ciències Mèdiques Bàsiques, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Sant Llorenç 21; 43201 Reus, Spain
E-mail: mariajose.figueras@urv.cat

Shiga toxins (Stx1 and Stx2) are important virulence factors in the pathogenesis of gastroenteritis, hemorrhagic colitis and haemolytic-uremic syndrome (HUS) [1–3]. They are usually encoded in the genome of bacteriophages (highly mobile elements) that play a role in Stx expression and horizontal gene transfer, leading to the emergence of new *stx*-variants or *stx*-producing pathogens [4]. Several variants of *stx1* and *stx2* genes have been recognized [2,3], with *stx2* (the prototype) and *stx2c* being considered the most important because they are more frequently associated with HUS than *stx1* and *stx2d*_{activatable} [2,3,5]. The *stx* genes show instability *in vivo* and *in vitro* as a result of the mobility of *stx*-phages [4,6], leading to the loss of *stx* genes after subculturing and/or infection [1,4,6–8].


Despite Shiga toxins being typical of *Shigella dysenteriae* and Shiga toxin-producing *E. coli* (STEC), they have also been described in species of other genera, including *Aeromonas* [7–12]. In *Aeromonas*, the presence of *stx1* gene has only been detected in five strains [11,12] but never sequenced, and it is not known whether they have the *stx2*. Despite that, several cases of HUS associated with *Aeromonas* have been reported [13]. The present study investigates the *stx* genes (*stx1* and *stx2*) in 80 human *Aeromonas* strains by PCR and sequencing.

All investigated strains (33 from extra-intestinal infections and 47 from diarrhoea) were genetically identified [14]. The strain of *Aeromonas veronii* bv. *sobria* associated with a case of HUS [13] was also tested. DNA was extracted from single colonies grown on sheep blood agar (24 h at 30°C) using InstaGene™ Matrix (Bio-Rad, Hercules, CA, USA). Separate PCRs for the detection of *stx1* (350 bp) and *stx2* (406 bp) with primers EVT-1&2 and EVS-1&2, respectively (TaKaRa Biomedicals, Tokyo, Japan) with positive and negative controls were employed [11]. PCR products were purified using GFX PCR DNA and the Gel Band Purification Kit (Amersham Biotech, Little Chalfont, UK) and sequenced on both strands using the TaKaRa primers (3.2 pmol/μL) in an ABI PRISM 310 genetic analyzer (Applied Biosystems, Foster City, CA, USA). Using CLUSTAL W, the *stx1* and *stx2* obtained sequences were independently aligned with those available in the GenBank to establish their similarity. Their genetic relationships were graphically represented as phylogenetic trees using the neighbour-joining method, as described previously [14].

Nineteen of the 80 *Aeromonas* strains showed a band of the expected size (350 bp) for the *stx1* and one of them also the band (406 bp) of *stx2*. However, in 15 of the 19 strains, the *stx1* bands were faint as was also the *stx2* band (Fig. 1a, b). The strain of *A. veronii* bv. *sobria* associated with a case of HUS [13] did not show even faint bands. To verify the results, the same DNA of the 19 *stx1*-positive strains was evaluated again under identical conditions and only four (875c, 883c, 885c and 887c) strains were positive for the *stx1*. Negative results corresponded with strains showing faint bands in the first analysis. The 19 *Aeromonas* strains were grown again from the glycerol stock and *stx1* was amplified from a new DNA extraction. The results obtained reproduced the initial finding, with the appearance of the same 15 strains with faint *stx1* bands and four with intense bands. The PCR for the *stx2*-positive strain (819c) was performed five times from four different DNA extractions from the same frozen stock and the expected band (406 bp) was only observed on two of five (40%) occasions as a faint band (Fig. 1c). These faint bands can be explained by the number of copies of *stx* genes in the template DNA [7] and their loss after subculture or infection agrees with previous findings [1,4,6–8], and may also explain the lack of amplification in the HUS isolate of *A. veronii* bv. *sobria*.

Snowden *et al.* [12] detected *stx1* in only one environmental strain of *A. veronii* using other primers [15]. We evaluated the same primers, although the expected 121 bp band of *stx1* could not be amplified in any of the 19 *stx1*-positive strains.

FIG. 1. Examples of PCR amplifications demonstrating the presence of *stx* genes in *Aeromonas* strains. 25 μ L of PCR product electrophoresed in 1% agarose gel. (a) *stx1* strong and faint bands. Lane 1, 875c; lane 2, 883c; lane 3, 885c; lane 4, 887c; lane 5, 194c; lane 6, 361c; lane 7, 191c; lane 8, 24c. (b) *stx2* faint bands. Lane 1, 875c; lane 2, 819c; lane 3, 819c (duplicate PCR product). (c) *stx1* amplified from plasmid DNA. Lane 1, 535c. Lane C+, positive control *Escherichia coli* O157:H (CECT 4076). Lane C-, negative control (Milli-Q water as template DNA; Millipore, Billerica, MA, USA). Lane M, Ladder 100 bp. *Aeromonas caviae* strains: 535c, 819c, 875c, 883c and 885c; *Aeromonas hydrophila* strains: 24c, 191c, 194c and 887c; *Aeromonas salmonicida* strain 361c.



We found more *stx1*-positive *Aeromonas* strains (23.75% 19/80) than in previous studies (10.25% 4/39) [11] and (9.1% 1/11) [12]. They were predominantly encountered in *Aeromonas caviae* (42.1% 8/19), *Aeromonas hydrophila* (31.6% 6/19) and *A. veronii* (10.5% 2/19), which are species commonly associated with gastroenteritis and even with a dysentery-like syndrome and HUS [13,16,17]. The only *stx1-stx2*-positive strain (819c) belonged to *A. caviae* and was isolated from a urine sample.

Sequences (350 bp) of *stx1* of the four *Aeromonas* strains with intense bands were identical and showed 99.71% similarity (one different nucleotide) to the corresponding region of this gene of *E. coli* O157:H7, whereas a 99.51% similarity (two different nucleotides) was shown for the *stx2* sequence of strain 819c (406 bp). The analysis showed that our *stx1* sequences clustered with those from *S. dysenteriae*, *Shigella sonnei*, *E. coli* O157:H7 and other STEC human isolates (Fig. 2a), whereas *A. caviae stx2* sequence clustered (Fig. 2b) with those of the most virulent human variants (*stx2* prototype and *stx2c*) that are commonly associated with HUS [2,3]. This may suggest an equally potential role of both genes in *Aeromonas* and horizontal gene transfer [4] among those microorganisms, which is not surprising because they inhabit the same environments.

To determine whether the observed instability of *stx1* was a result of its extra-chromosomal DNA location, this DNA, from strains 535c representative of strains with a faint band,

and 887c with a strong band, was extracted using Ultraclean 6 minute mini plasmid prep kit (Mo Bio, Carlsbad, CA, USA). A single band (approximately 3.2 kbp) of extra-chromosomal DNA was obtained from both strains. This DNA was used as a template for *stx1*-PCR amplification [11] and a band of the expected size (350 bp) for *stx1* as intense as the positive control (*E. coli* O157:H7) was only observed from strain 535c (Fig. 1c). This indicated that, at least in strain 535c and in the four strains reported by Haque *et al.* [11], the *stx1* is not chromosomally encoded. These results corroborate the mobility of the *stx*-phages that can be lost by subculturing [4].

To determine the production of Stx1 and Stx2 toxins by the PCR positive strains, a rapid immunochromatographic test (Duopath Verotoxin test; Merck, Darmstadt, Germany) was used. Only strains 885c (which showed an intense *stx1* band by PCR) and 535c (with a faint PCR band) showed a weak Stx1 signal, although none of the strains showed a Stx2 positive reaction. In conclusion, 10.53% (2/19) of the *Aeromonas* strains that possessed *stx1* produced the Stx1 toxin. Similar values (using the same test) have been reported from STEC strains (6.7% produced Stx1 and 6–7% produced Stx2) from human wastewater [18]. However, the results obtained in the present study could be influenced by the fact that this test is specifically designed for STEC toxins.




FIG. 2. Phylogenetic analysis of nucleotide sequence fragments (350 bp) of *stx*₁ genes (a) and (406-bp) of *stx*₂ genes (b) of *Aeromonas* and other enterobacteria. Phylogenetic trees were constructed with the neighbour-joining method using Kimura's two-parameter model. Bootstrap values greater than 50 from 1000 replicate trees are reported at the nodes. The scale bar indicates evolutionary distance of 0.01 and 0.05 nucleotide substitutions per site in (a) and (b), respectively. All numbers and accession numbers are given as cited in the GenBank database.

To our knowledge, this is the first report to provide *Aeromonas stx1* and *stx2* sequences that establish their high similarity with those of STEC. This is of particular importance because these genes have been poorly studied in *Aeromonas* and they may have a role in inducing diarrhoea and HUS.

The sequences of the *stx1* and *stx2* genes have been deposited in GenBank under accession numbers GUI30282-GUI30285 and GUI30286, respectively.

Acknowledgements

We thank R Bartolomé, G. Prats, J. Vila, I. Pujol, F. Ballester, J. Reina and E. Hofer for providing clinical strains. We are grateful to M. Muniesa (University of Barcelona) and to J. Pastor, J. Guarro and R. Beaz (University Rovira i Virgili) for their valuable help and suggestions.

Transparency Declaration

Part of this work was supported by funds from the European Commission for the HEALTHY WATER Project (FOOD-CT-2006-036306). However, the authors are solely responsible for the content of this publication and it does not represent the opinion of the European Commission. The European Commission is not responsible for any use that might be made of data appearing therein. The authors have no conflicts of interest.

References

- Friedrich AW, Zhang WL, Bielaszewska M *et al.* Prevalence, virulence profiles and clinical significance of Shiga toxin-negative variants of enterohemorrhagic *Escherichia coli* O157 infection in humans. *Clin Infect Dis* 2007; 45: 39–45.

2. Lee JE, Reed J, Shields MS, Spiegel KM, Farrell LD, Sheridan PP. Phylogenetic analysis of Shiga toxin 1 and Shiga toxin 2 genes associated with disease outbreaks. *BMC Microbiol* 2007; 7: 109.
3. Orth D, Grif K, Khan AB, Naim A, Dierich MP, Wurznner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. *Diagn Microbiol Infect Dis* 2007; 59: 235–242.
4. Herold S, Karch K, Schmidt H. Shiga-toxin-converting bacteriophages. Genomes in motion. *Int J Med Microbiol* 2004; 294: 115–121.
5. Bielaszewska M, Friedrich AW, Aldick T, Schürk-Bulgrin R, Karch H. Shiga toxin activatable by intestinal mucus in *Escherichia coli* isolated from humans: predictor for a severe clinical outcome. *Clin Infect Dis* 2006; 43: 1160–1167.
6. Karch H, Meyer T, Russmann H, Heesemann J. Frequent loss of Shiga-like toxin genes in clinical isolates of *Escherichia coli* upon subcultivation. *Infect Immun* 1992; 60: 3464–3467.
7. Schmidt H, Montag M, Bockemuhl J, Heesemann J, Karch H. Shiga-like toxin II-related cytotoxins in *Citrobacter freundii* strains from humans and beef samples. *Infect Immun* 1993; 61: 534–543.
8. Paton JC, Paton AW. Instability of a Shiga toxin type 2 gene in *Enterobacter cloacae*. *J Clin Microbiol* 1997; 35: 1917.
9. O'Brien AD, Chen ME, Holmes RK, Kaper J, Levine MM. Environmental and human isolates of *Vibrio cholerae* and *Vibrio parahaemolyticus* produce a Shigella dysenteriae I (Shiga)-like cytotoxin. *Lancet* 1984; 1: 77–78.
10. Grotiuz G, Sirok A, Gadea P, Varela G, Schelotto F. Shiga toxin 2-producing *Acinetobacter haemolyticus* associated with a case of bloody diarrhea. *J Clin Microbiol* 2006; 44: 3838–3841.
11. Haque QM, Sugiyama A, Iwade Y, Midorikawa Y, Yamauchi T. Diarrheal and environmental isolates of *Aeromonas* spp. produce a toxin similar to Shiga-like toxin I. *Curr Microbiol* 1996; 32: 239–245.
12. Snowden L, Wernbacher L, Stenzel D et al. Prevalence of environmental *Aeromonas* in South East Queensland, Australia: a study of their interactions with human monolayer Caco-2 cells. *J Appl Microbiol* 2006; 101: 964–975.
13. Figueras MJ, Aldea MJ, Fernandez N, Aspiroz C, Alperi A, Guarro J. *Aeromonas* hemolytic uremic syndrome. A case and a review of the literature. *Diagn Microbiol Infect Dis* 2007; 58: 231–234.
14. Alperi A, Figueras MJ, Inza I, Martínez-Murcia AJ. Analysis of 16S rRNA gene mutations in a subset of *Aeromonas* strains and their impact in species delineation. *Int Microbiol* 2008; 11: 185–194.
15. Pass MA, Odera R, Batt RM. Multiplex PCRs for identification of *Escherichia coli* virulence genes. *J Clin Microbiol* 2000; 38: 2001–2004.
16. Figueras MJ. Clinical relevance of *Aeromonas*. *Rev Med Microbiol* 2005; 16: 145–153.
17. Figueras MJ, Horneman AJ, Martínez-Murcia A, Guarro J. Controversial data on the association of *Aeromonas* with diarrhoea in a recent Hong Kong study. *J Med Microbiol* 2007; 56: 996–998.
18. García-Aljaro C, Muniesa M, Blanco JE et al. Characterization of Shiga toxin-producing *Escherichia coli* isolated from aquatic environments. *FEMS Microbiol Lett* 2005; 246: 55–65.